French Biotech Stock News

If you are wondering whether Sanofi at €81.90 is priced for opportunity or risk, the starting point is understanding what the current share price actually implies about the business. The stock has recently moved 6.6% over the last 7 days, while the 1 year return of a 16.1% decline and a slightly negative year to date result of a 0.5% decline suggest sentiment has been cautious despite a 5 year gain of 18.5%. Recent headlines have focused on Sanofi's position as a major global pharmaceuticals...

DigiKey announced in March 2026 that it had launched an enhanced version of STMicroelectronics’ free eDesignSuite platform, integrating Ultra Librarian’s models, advanced simulation, multi-CAD exports, and direct DigiKey bill-of-materials purchasing for ST components. This deeper tool integration tightens STMicroelectronics’ link to engineers’ everyday workflows, potentially increasing stickiness of its power, signal conditioning and NFC/RFID solutions in a competitive semiconductor...

ABIVAX Société Anonyme (ENXTPA:ABVX) is in focus after full year 2025 earnings showed revenue of €4.57 million and a net loss of €336.1 million, alongside fresh trial, leadership, financing, and index inclusion updates. See our latest analysis for ABIVAX Société Anonyme. The recent earnings release, positive Phase 3 safety update, leadership hires, ESOP related shelf registration, and FTSE All World Index inclusion come against a backdrop of a 1 year total shareholder return above 10x. At the...

Why Compagnie de l'Odet's latest earnings and dividend plans matter Compagnie de l'Odet (ENXTPA:ODET) combined softer full year 2025 results with a proposed higher cash dividend, a mix that gives you fresh information on both business performance and shareholder payout priorities. See our latest analysis for Compagnie de l'Odet. The latest mix of softer 2025 earnings and a higher proposed dividend appears to have supported a short burst of buying interest, with a 7 day share price return of...

Vetoquinol (ENXTPA:VETO) shares are back in focus after the Board approved the 2025 financial statements and announced plans to propose a €0.93 per share dividend to shareholders in May. See our latest analysis for Vetoquinol. That proposed €0.93 dividend comes as the share price, now at €78.9, has seen a 6.9% decline over 1 month and a 6.5% share price return decline year to date. The 1 year total shareholder return is 3%, suggesting recent momentum has softened compared with longer term...

Wondering whether Compagnie Générale des Établissements Michelin Société en commandite par actions is attractively priced or already fully valued? This article walks you through key signals so you can judge the stock's current price with more confidence. The share price recently closed at €28.97, with returns of 1.0% over 7 days, a 15.8% decline over 30 days, a 1.1% gain year to date, and a 7.0% decline over the last year, set against a 15.8% gain over 3 years. Recent coverage has focused on...

ADLPartner (ENXTPA:DKUPL) has set the tone for FY 2025 with first half revenue of €117.4 million and basic EPS of €0.96, alongside trailing twelve month revenue of €230.6 million and EPS of €2.10 that frame how the latest figures sit within the past year’s performance. Over the last three reported halves, revenue has moved from €104.6 million in 1H 2024 to €113.2 million in 2H 2024 and then to €117.4 million in 1H 2025, while basic EPS shifted from €1.40 to €1.14 and then €0.96. This sets up...

If you are wondering whether Airbus is fairly priced or offering value at current levels, it helps to start with how its market performance lines up against underlying worth. The share price recently closed at €159.18, with returns of a 4.3% decline over 7 days, a 13.6% decline over 30 days, a 21.9% decline year to date, and around 0.0% over the last year, compared with 34.1% over 3 years and 69.6% over 5 years. Recent headlines around Airbus have focused on its role as a key aerospace and...

L'Oréal (ENXTPA:OR) has recently drawn investor attention after a one-month return decline of 11.6%, alongside a three-month return decline of 4.3%, prompting closer inspection of its current valuation and fundamentals. See our latest analysis for L'Oréal. At a share price of €351.25, L'Oréal’s recent 1 month share price return of an 11.6% decline contrasts with a positive 1 year total shareholder return of 4.3%. This suggests near term momentum has faded even as longer term holders remain...

Investors may be wondering whether Tikehau Capital at €15.62 is starting to look interesting, or if the market is still pricing in too much risk. The stock has been choppy, with a 1.2% gain over the last 7 days, a 17.4% decline over the past month, and returns of a 1.1% decline year to date and a 14.7% decline over the last year. These moves come as investors reassess listed capital markets groups in general, reacting to shifting views on asset flows, fee sustainability, and balance sheet...

Why TotalEnergies (ENXTPA:TTE) is on investors’ radar today TotalEnergies (ENXTPA:TTE) has attracted attention after a strong recent run, with the share price showing positive returns over the past month and past 3 months against a backdrop of steady reported revenue and net income. See our latest analysis for TotalEnergies. That move comes on top of a 39.91% year to date share price return and a 37.95% total shareholder return over the past year, suggesting momentum has been building over...

Investors may be asking whether Air France KLM at €8.75 is starting to look like value, or if the risks still outweigh the potential upside. The stock is down 5.6% over the last week and 28.9% over the past month, while the 1 year return is 2.5%. These moves come as investors reassess airline stocks in general, with sentiment often swinging quickly on changes in travel demand, fuel costs, and regulatory signals. For Air France KLM, this context helps explain why the share price can react...

Eurazeo (ENXTPA:RF) has been removed from the FTSE All-World Index. The change affects the stock’s presence in a major global equity benchmark tracked by index funds and ETFs. This type of index action can influence trading activity and how institutional investors view the company. Eurazeo is a listed investment company with exposure to private equity style assets, which means its share often sits on the radar of global fund managers. Being dropped from a widely followed index such as the...

Why Elis is on investors’ radar today Elis (ENXTPA:ELIS) has drawn attention after recent share price pressure, with the stock down about 11% over the past month and slightly lower over the past 3 months. This has prompted fresh interest in its valuation. See our latest analysis for Elis. Despite the recent 11% 30 day share price decline and softer short term momentum, Elis still carries a 1 year total shareholder return of about 20% and an approximately 84% total shareholder return over 5...

Investors were underwhelmed by the solid earnings posted by SergeFerrari Group SA ( EPA:SEFER ) recently. We have done...

The market for Capgemini SE's ( EPA:CAP ) shares didn't move much after it posted weak earnings recently. We think that...

One of the biggest stories of last week was how STIF Société anonyme ( EPA:ALSTI ) shares plunged 26% in the week since...

As the European markets navigate through uncertainties spurred by geopolitical tensions and energy price fluctuations, investor sentiment remains cautious yet discerning. In such a climate, growth companies with high insider ownership often stand out as potentially resilient investments due to the alignment of interests between insiders and shareholders, which can be particularly advantageous during periods of economic volatility.

The European markets have been navigating a landscape marked by geopolitical tensions and fluctuating energy prices, with the pan-European STOXX Europe 600 Index showing modest gains. Amidst this backdrop, investors are increasingly looking at diverse investment avenues to capitalize on potential opportunities. Penny stocks, often representing smaller or newer companies, remain an intriguing area for those seeking growth at lower price points. Although the term might seem outdated, these...

Today is shaping up negative for 2CRSI S.A. ( EPA:AL2SI ) shareholders, with the analysts delivering a substantial...

As you might know, Cegedim SA ( EPA:ALCGM ) last week released its latest full-year, and things did not turn out so...

Bolloré (ENXTPA:BOL) has drawn fresh attention after its board proposed an exceptional €1.5 per share dividend, about €4.2b, alongside 2025 results and a regular €0.08 per share dividend plan. See our latest analysis for Bolloré. The exceptional dividend proposal and 2025 earnings release have arrived after a mixed period, with a 3.96% three month share price return, a 1.17% year to date share price gain, but a 1 year total shareholder return decline of 11.46%, suggesting short term momentum...

Recent share performance and current context Pernod Ricard (ENXTPA:RI) has seen its share price move unevenly, with a roughly flat 7 day return, a double digit decline over the past month, and a smaller negative move across the past 3 months. See our latest analysis for Pernod Ricard. The recent 7.9% 1 day share price return to €64.7 comes after a 17.3% 30 day share price decline and sits against a 27.4% 1 year total shareholder return loss, suggesting momentum has been fading over a longer...

Sanofi received FDA Breakthrough Therapy designation for oral venglustat targeting neurological symptoms in type 3 Gaucher disease. Sanofi reported positive phase 3 results for amlitelimab in atopic dermatitis. European regulators issued a positive opinion for Sarclisa subcutaneous with an on body injector for multiple myeloma, potentially introducing dual administration modes in the EU. Sanofi, traded as ENXTPA:SAN, is currently priced at €81.99 and has seen a 5.4% gain over the past week,...